OBJECTIVES

: The incidence of peripheral T-cell lymphoma (PTCL) and Cutaneous T-cell lymphoma (CTCL) are found to be higher in developed countries.

The objective of this study was to assess and compare the risk and patterns of treatment among PTCL and CTCL between China and the United States.

METHODS

: To estimate the respective sizes of the incident populations, we collated data from the respective national cancer registries.

To estimate treatment patterns, we fielded a survey among hematologist oncologists practicing for at least two years in the USA and China. Surveys were fielded from January to February 2020.

The survey asked, for incident patients, what percentage were treated with anti-neoplastic drug treatment as a 1^st and 2^nd line of therapy, and of those that were treated, what percentage were eligible for a subsequent line of therapy.

RESULTS

: The 1^st line percent drug treated among CTCL is 72% and 48% in United States and China respectively. In PTCL 1^st line percent drug treated is 81% and 47% in the USA and China respectively. In CTCL after 1^st line therapy, proportion of patients progressing to 2^nd line is 66% in the USA and 40% in China. The proportion of patients progressing to 2^nd line after 1^st line therapy in PTCL is 66% and 42% in the USA and China respectively.

The 2^nd line percent drug treated among CTCL is 70% and 45% in the USA and China respectively. In PTCL 2^nd line percent drug treated is 71% and 48% in China and the USA respectively.

CONCLUSIONS

: The percent drug treated in 1^st line therapy is higher in the USA as compared to China.

Progression to 2^nd line after 1^st line treatment is lower in China as compared to the USA. The percent drug treated in 2^nd line of therapy is higher in the USA than China.